Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools

Lamberth, Kasper; Reedtz-Runge, Stine Louise; Simon, Jonathan; Klementyeva, Ksenia; Pandey, Gouri Shankar; Padkjær, Søren Berg; Pascal, Véronique; León, Ileana R.; Gudme, Charlotte Nini; Buus, Søren; Sauna, Zuben E.

doi:10.1126/scitranslmed.aag1286

Title: Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools

Abstract

A computational and experimental strategy assesses the immunogenicity risk of bioengineered therapeutic proteins.

Authors:

Lamberth, Kasper ^[1]; Reedtz-Runge, Stine Louise ^[1]; Simon, Jonathan ^[2]; Klementyeva, Ksenia ^[2]; Pandey, Gouri Shankar ^[2]; Padkjær, Søren Berg ^[1]; Pascal, Véronique ^[1]; León, Ileana R. ^[1]; Gudme, Charlotte Nini ^[1]; Buus, Søren ^[3]; Sauna, Zuben E. ^[2]

Global Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark.
Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapeutics, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.
Laboratory of Experimental Immunology, Faculty of Health Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark.

Publication Date:: Wed Jan 11 00:00:00 EST 2017

Sponsoring Org.:: USDOE

OSTI Identifier:: 1434379

Resource Type:: Published Article

Journal Name:: Science Translational Medicine

Additional Journal Information:: Journal Name: Science Translational Medicine Journal Volume: 9 Journal Issue: 372; Journal ID: ISSN 1946-6234

Publisher:: American Association for the Advancement of Science (AAAS)

Country of Publication:: United States

Language:: English

Citation Formats


                    Lamberth, Kasper, Reedtz-Runge, Stine Louise, Simon, Jonathan, Klementyeva, Ksenia, Pandey, Gouri Shankar, Padkjær, Søren Berg, Pascal, Véronique, León, Ileana R., Gudme, Charlotte Nini, Buus, Søren, and Sauna, Zuben E. Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools.  United States: N. p., 2017. 
Web.  doi:10.1126/scitranslmed.aag1286.

Copy to clipboard


                    Lamberth, Kasper, Reedtz-Runge, Stine Louise, Simon, Jonathan, Klementyeva, Ksenia, Pandey, Gouri Shankar, Padkjær, Søren Berg, Pascal, Véronique, León, Ileana R., Gudme, Charlotte Nini, Buus, Søren, & Sauna, Zuben E. Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools.  United States.  https://doi.org/10.1126/scitranslmed.aag1286

Copy to clipboard


                    Lamberth, Kasper, Reedtz-Runge, Stine Louise, Simon, Jonathan, Klementyeva, Ksenia, Pandey, Gouri Shankar, Padkjær, Søren Berg, Pascal, Véronique, León, Ileana R., Gudme, Charlotte Nini, Buus, Søren, and Sauna, Zuben E. Wed .  
"Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools".  United States.  https://doi.org/10.1126/scitranslmed.aag1286.

Copy to clipboard


                    
@article{osti_1434379,

  title        = {Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools},

  author       = {Lamberth, Kasper and Reedtz-Runge, Stine Louise and Simon, Jonathan and Klementyeva, Ksenia and Pandey, Gouri Shankar and Padkjær, Søren Berg and Pascal, Véronique and León, Ileana R. and Gudme, Charlotte Nini and Buus, Søren and Sauna, Zuben E.},

  abstractNote = {A computational and experimental strategy assesses the immunogenicity risk of bioengineered therapeutic proteins.},

  doi          = {10.1126/scitranslmed.aag1286},

  journal      = {Science Translational Medicine},

  number       = 372,

  volume       = 9,

  place        = {United States},

  year         = {Wed Jan 11 00:00:00 EST 2017},

  month        = {Wed Jan 11 00:00:00 EST 2017}

}

Copy to clipboard

Journal Article:

Free Publicly Available Full Text

Publisher's Version of Record
https://doi.org/10.1126/scitranslmed.aag1286

Other availability

Search WorldCat to find libraries that may hold this journal

Citation Metrics:

Cited by: 43 works

Citation information provided by
Web of Science

Save / Share:

Export Metadata

Save to My Library

Works referenced in this record:

Polymorphisms in the F8 Gene and MHC-II Variants as Risk Factors for the Development of Inhibitory Anti-Factor VIII Antibodies during the Treatment of Hemophilia A: A Computational Assessment
journal, May 2013

Pandey, Gouri Shankar; Yanover, Chen; Howard, Tom E.
PLoS Computational Biology, Vol. 9, Issue 5
DOI: 10.1371/journal.pcbi.1003066

A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models
journal, March 2013

Stennicke, Henning R.; Kjalke, Marianne; Karpf, Ditte M.
Blood, Vol. 121, Issue 11
DOI: 10.1182/blood-2012-01-407494

Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain
journal, February 2012

Herczenik, Eszter; van Haren, Simon D.; Wroblewska, Aleksandra
Journal of Allergy and Clinical Immunology, Vol. 129, Issue 2
DOI: 10.1016/j.jaci.2011.08.029

TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity
journal, August 2016

Mahlangu, J.; Paz, P.; Hardtke, M.
Haemophilia, Vol. 22, Issue 6
DOI: 10.1111/hae.12994

Pharmacogenetics and the immunogenicity of protein therapeutics
journal, October 2011

Yanover, Chen; Jain, Nisha; Pierce, Glenn
Nature Biotechnology, Vol. 29, Issue 10
DOI: 10.1038/nbt.2002

A large synthetic peptide and phosphopeptide reference library for mass spectrometry–based proteomics
journal, May 2013

Marx, Harald; Lemeer, Simone; Schliep, Jan Erik
Nature Biotechnology, Vol. 31, Issue 6
DOI: 10.1038/nbt.2585

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity
journal, October 2015

Mahlangu, J. N.; Weldingh, K. N.; Lentz, S. R.
Journal of Thrombosis and Haemostasis, Vol. 13, Issue 11
DOI: 10.1111/jth.13141

Regulation of T Cell Immunity by Dendritic Cells
journal, August 2001

Lanzavecchia, Antonio; Sallusto, Federica
Cell, Vol. 106, Issue 3
DOI: 10.1016/S0092-8674(01)00455-X

Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity
journal, November 2001

Persson, E.; Kjalke, M.; Olsen, O. H.
Proceedings of the National Academy of Sciences, Vol. 98, Issue 24
DOI: 10.1073/pnas.241339498

Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry
journal, October 2013

Gragert, Loren; Madbouly, Abeer; Freeman, John
Human Immunology, Vol. 74, Issue 10
DOI: 10.1016/j.humimm.2013.06.025

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study
journal, September 2006

Astermark, Jan; Donfield, Sharyne M.; DiMichele, Donna M.
Blood, Vol. 109, Issue 2
DOI: 10.1182/blood-2006-04-017988

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)
journal, February 2014

Zollner, S.; Schuermann, D.; Raquet, E.
Journal of Thrombosis and Haemostasis, Vol. 12, Issue 2
DOI: 10.1111/jth.12477

Robust Prediction of the MASCOT Score for an Improved Quality Assessment in Mass Spectrometric Proteomics
journal, September 2008

Koenig, Thomas; Menze, Bjoern H.; Kirchner, Marc
Journal of Proteome Research, Vol. 7, Issue 9
DOI: 10.1021/pr700859x

Plasma derivatives: New products and new approaches
journal, May 2012

Sauna, Zuben E.; Pandey, Gouri Shankar; Jain, Nisha
Biologicals, Vol. 40, Issue 3
DOI: 10.1016/j.biologicals.2011.11.003

Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia: BAY 86-6150 in hemophilia
journal, May 2012

Mahlangu, J. N.; Coetzee, M. J.; Laffan, M.
Journal of Thrombosis and Haemostasis, Vol. 10, Issue 5
DOI: 10.1111/j.1538-7836.2012.04667.x

Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database
journal, July 2013

Puetz, J.; Soucie, J. M.; Kempton, C. L.
Haemophilia, Vol. 20, Issue 1
DOI: 10.1111/hae.12229

Building better drugs: developing and regulating engineered therapeutic proteins
journal, October 2013

Kimchi-Sarfaty, Chava; Schiller, Tal; Hamasaki-Katagiri, Nobuko
Trends in Pharmacological Sciences, Vol. 34, Issue 10
DOI: 10.1016/j.tips.2013.08.005

The Kinetic Stability of MHC Class II:Peptide Complexes Is a Key Parameter that Dictates Immunodominance
journal, July 2005

Lazarski, Christopher A.; Chaves, Francisco A.; Jenks, Scott A.
Immunity, Vol. 23, Issue 1
DOI: 10.1016/j.immuni.2005.05.009

A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach
journal, April 2008

Wang, Peng; Sidney, John; Dow, Courtney
PLoS Computational Biology, Vol. 4, Issue 4
DOI: 10.1371/journal.pcbi.1000048

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry
journal, March 2005

Parameswaran, R.; Shapiro, A. D.; Gill, J. C.
Haemophilia, Vol. 11, Issue 2
DOI: 10.1111/j.1365-2516.2005.01075.x

Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size
journal, August 1992

Chicz, Roman M.; Urban, Robert G.; Lane, William S.
Nature, Vol. 358, Issue 6389
DOI: 10.1038/358764a0

Functional recombinant MHC class II molecules and high-throughput peptide-binding assays
journal, January 2009

Justesen, Sune; Harndahl, Mikkel; Lamberth, Kasper
Immunome Research, Vol. 5, Issue 1
DOI: 10.1186/1745-7580-5-2

Haemophilias A and B
journal, May 2003

Bolton-Maggs, Paula HB; Pasi, K. John
The Lancet, Vol. 361, Issue 9371
DOI: 10.1016/S0140-6736(03)13405-8

Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors
journal, June 2004

Abshire, T.; Kenet, G.
Journal of Thrombosis and Haemostasis, Vol. 2, Issue 6
DOI: 10.1111/j.1538-7836.2004.00759.x

Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors: A multi-centre, randomised, double-blind, cross-over trial
journal, January 2006

Kavakli, Khan; Makris, Mike; Zulfikar, Bulent
Thrombosis and Haemostasis, Vol. 95, Issue 04
DOI: 10.1160/TH05-07-0510

Quantitative Predictions of Peptide Binding to Any HLA-DR Molecule of Known Sequence: NetMHCIIpan
journal, July 2008

Nielsen, Morten; Lundegaard, Claus; Blicher, Thomas
PLoS Computational Biology, Vol. 4, Issue 7
DOI: 10.1371/journal.pcbi.1000107

Limited Promiscuity of HLA-DRB1 Presented Peptides Derived of Blood Coagulation Factor VIII
journal, November 2013

van Haren, Simon D.; Wroblewska, Aleksandra; Herczenik, Eszter
PLoS ONE, Vol. 8, Issue 11
DOI: 10.1371/journal.pone.0080239

Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006)
journal, September 2009

Chitlur, M.; Warrier, I.; Rajpurkar, M.
Haemophilia, Vol. 15, Issue 5
DOI: 10.1111/j.1365-2516.2009.02039.x

Similar Records in DOE PAGES and OSTI.GOV collections:

Structural, Functional, and Immunogenic Insights on Cu,Zn Superoxide Dismutase Pathogenic Virulence Factors from Neisseria meningitidis and Brucella abortus

Journal Article Pratt, Ashley J. ; DiDonato, Michael ; Shin, David S. ; ... - Journal of Bacteriology

ABSTRACT Bacterial pathogensNeisseria meningitidisandBrucella abortuspose threats to human and animal health worldwide, causing meningococcal disease and brucellosis, respectively. Mortality from acuteN. meningitidisinfections remains high despite antibiotics, and brucellosis presents alimentary and health consequences. Superoxide dismutases are master regulators of reactive oxygen and general pathogenicity factors and are therefore therapeutic targets. Cu,Zn superoxide dismutases (SODs) localized to the periplasm promote survival by detoxifying superoxide radicals generated by major host antimicrobial immune responses. We discovered that passive immunization with an antibody directed atN. meningitidisSOD (NmSOD) was protective in a mouse infection model. To define the relevant atomic details and solution assembly statesmore »« less
https://doi.org/10.1128/JB.00343-15

Full Text Available
Structural, functional and immunogenic insights on Cu,Zn superoxide dismutase pathogenic virulence factors from Neisseria meningitidis and Brucella abortus

Journal Article Pratt, Ashley J. ; DiDonato, Michael ; Shin, David S. ; ... - Journal of Bacteriology

Bacterial pathogens Neisseria meningitidis and Brucella abortus pose threats to human and animal health worldwide, causing meningococcal disease and brucellosis, respectively. Mortality from acute N. meningitidis infections remains high despite antibiotics, and brucellosis presents alimentary and health consequences. Superoxide dismutases are master regulators of reactive oxygen and general pathogenicity factors and are therefore therapeutic targets. Cu,Zn superoxide dismutases (SODs) localized to the periplasm promote survival by detoxifying superoxide radicals generated by major host antimicrobial immune responses. We discovered that passive immunization with an antibody directed at N. meningitidis SOD (NmSOD) was protective in a mouse infection model. To define themore »« less
Cited by 14
https://doi.org/10.1128/JB.00343-15

Full Text Available
RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences

Journal Article Burley, Stephen K. ; Bhikadiya, Charmi ; Bi, Chunxiao ; ... - Nucleic Acids Research

Abstract The Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB), the US data center for the global PDB archive and a founding member of the Worldwide Protein Data Bank partnership, serves tens of thousands of data depositors in the Americas and Oceania and makes 3D macromolecular structure data available at no charge and without restrictions to millions of RCSB.org users around the world, including >660 000 educators, students and members of the curious public using PDB101.RCSB.org. PDB data depositors include structural biologists using macromolecular crystallography, nuclear magnetic resonance spectroscopy, 3D electron microscopy and micro-electron diffraction. PDB data consumers accessingmore »« less
https://doi.org/10.1093/nar/gkaa1038
BFD-22 a new potential inhibitor of BRAF inhibits the metastasis of B16F10 melanoma cells and simultaneously increased the tumor immunogenicity

Journal Article Ferreira, Adilson Kleber, E-mail: ferreira-kleber@usp.br ; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen ; Pasqualoto, Kerly Fernanda Mesquita ; ... - Toxicology and Applied Pharmacology

Benzofuroxan is an interesting ring system, which has shown a wide spectrum of biological responses against tumor cell lines. We investigated, herein, the antitumor effects of benzofuroxan derivatives (BFDs) in vitro and in a melanoma mouse model. Cytotoxic effects of twenty-two BFDs were determined by MTT assay. Effects of BFD-22 in apoptosis and cell proliferation were evaluated using Annexin V-FITC/PI and CFSE staining. In addition, the effects in the cell cycle were assessed. Flow cytometry, western blot, and fluorescence microscopy analysis were employed to investigate the apoptosis-related proteins and the BRAF signaling. Cell motility was also exploited through cell invasionmore »« less
https://doi.org/10.1016/J.TAAP.2016.02.008
Assessing the transport and fate of bioengineered microorganisms in the environment

Conference Barnthouse, L W ; Palumbo, A V

We review the methods currently available for quantifying the transport and fate of microbes in atmospheric and aqueous media and assess their adequacy for purposes of risk assessment. We review the literature on transport and fate of microorganisms, including studies of: (1) pathways of migration, (2) the survival of microorganisms during transport and fate. In addition, we review the transport and fate models that have been used in environmental risk assessments for radionuclides and toxic chemicals and evaluate their applicability to the problem of assessing environmental risks of bioengineered microorganisms.
Full Text Available

Similar Records

Title: Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools

Abstract

Citation Formats

Polymorphisms in the F8 Gene and MHC-II Variants as Risk Factors for the Development of Inhibitory Anti-Factor VIII Antibodies during the Treatment of Hemophilia A: A Computational Assessment journal, May 2013

A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models journal, March 2013

Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain journal, February 2012

TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity journal, August 2016

Pharmacogenetics and the immunogenicity of protein therapeutics journal, October 2011

A large synthetic peptide and phosphopeptide reference library for mass spectrometry–based proteomics journal, May 2013

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity journal, October 2015

Regulation of T Cell Immunity by Dendritic Cells journal, August 2001

Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity journal, November 2001

Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry journal, October 2013

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study journal, September 2006

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) journal, February 2014

Robust Prediction of the MASCOT Score for an Improved Quality Assessment in Mass Spectrometric Proteomics journal, September 2008

Plasma derivatives: New products and new approaches journal, May 2012

Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia: BAY 86-6150 in hemophilia journal, May 2012

Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database journal, July 2013

Building better drugs: developing and regulating engineered therapeutic proteins journal, October 2013

The Kinetic Stability of MHC Class II:Peptide Complexes Is a Key Parameter that Dictates Immunodominance journal, July 2005

A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach journal, April 2008

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry journal, March 2005

Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size journal, August 1992

Functional recombinant MHC class II molecules and high-throughput peptide-binding assays journal, January 2009

Haemophilias A and B journal, May 2003

Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors journal, June 2004

Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors: A multi-centre, randomised, double-blind, cross-over trial journal, January 2006

Quantitative Predictions of Peptide Binding to Any HLA-DR Molecule of Known Sequence: NetMHCIIpan journal, July 2008

Limited Promiscuity of HLA-DRB1 Presented Peptides Derived of Blood Coagulation Factor VIII journal, November 2013

Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006) journal, September 2009

Polymorphisms in the F8 Gene and MHC-II Variants as Risk Factors for the Development of Inhibitory Anti-Factor VIII Antibodies during the Treatment of Hemophilia A: A Computational Assessment
journal, May 2013

A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models
journal, March 2013

Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain
journal, February 2012

TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity
journal, August 2016

Pharmacogenetics and the immunogenicity of protein therapeutics
journal, October 2011

A large synthetic peptide and phosphopeptide reference library for mass spectrometry–based proteomics
journal, May 2013

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity
journal, October 2015

Regulation of T Cell Immunity by Dendritic Cells
journal, August 2001

Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity
journal, November 2001

Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry
journal, October 2013

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study
journal, September 2006

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)
journal, February 2014

Robust Prediction of the MASCOT Score for an Improved Quality Assessment in Mass Spectrometric Proteomics
journal, September 2008

Plasma derivatives: New products and new approaches
journal, May 2012

Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia: BAY 86-6150 in hemophilia
journal, May 2012

Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database
journal, July 2013

Building better drugs: developing and regulating engineered therapeutic proteins
journal, October 2013

The Kinetic Stability of MHC Class II:Peptide Complexes Is a Key Parameter that Dictates Immunodominance
journal, July 2005

A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach
journal, April 2008

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry
journal, March 2005

Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size
journal, August 1992

Functional recombinant MHC class II molecules and high-throughput peptide-binding assays
journal, January 2009

Haemophilias A and B
journal, May 2003

Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors
journal, June 2004

Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors: A multi-centre, randomised, double-blind, cross-over trial
journal, January 2006

Quantitative Predictions of Peptide Binding to Any HLA-DR Molecule of Known Sequence: NetMHCIIpan
journal, July 2008

Limited Promiscuity of HLA-DRB1 Presented Peptides Derived of Blood Coagulation Factor VIII
journal, November 2013

Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006)
journal, September 2009